Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study on Dose-Escalation Tolerability and Pharmacokinetics of AL58805 in Patients With Advanced Tumors

NCT07179081 is registered in ClinicalTrials.gov with Advenchen Laboratories Nanjing Ltd. as lead sponsor.

NCT NCT07179081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07179081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study on Dose-Escalation Tolerability and Pharmacokinetics of AL58805 in Patients With Advanced Tumors
Lead sponsor
Advenchen Laboratories Nanjing Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
December 20, 2020
Completion date
January 26, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced tumors